卡博替尼治疗转移性肾细胞癌的真实世界证据:CABOREAL早期获取项目结果
中位总生存期为14.4个月,12个月总生存率为56.5%(95%CI 51.5-61.2)。以60 mg/日起始治疗与更长总生存相关。
要点
- 中位总生存期14.4个月,12个月总生存率56.5%(95%CI 51.5-61.2)。
- 以60 mg/日起始治疗与更长总生存相关(p=0.0486)。
- 57.0%患者经历剂量减少,中位平均日剂量为40.0 mg。
核心结论
- 在迄今最大的真实世界研究中,卡博替尼在未经选择的、经多线治疗的转移性肾细胞癌患者中有效。
- 以60 mg/日起始治疗与改善的结局相关。
研究设计与样本
- 多中心(n=26)、观察性、回顾性研究,纳入接受至少1剂卡博替尼的转移性肾细胞癌患者。
- 采用Kaplan-Meier法估计总生存期,log-rank检验比较亚组,多因素Cox回归模型评估卡博替尼起始后总生存期的预测因素。
主要发现
- 患者特征:ECOG体能状态≥2者占39.3%;IMDC风险差者占31.7%;既往治疗线数为0-1、2和≥3者分别占25.3%、33.4%和41.2%;骨转移占55.9%;脑转移占16.8%。
- 中位随访时间为14.4(范围0-30)个月,中位治疗持续时间为7.6(Q1-Q3 0.1-29.1)个月,中位总生存期为14.4个月,12个月总生存率为56.5%(95%CI 51.5-61.2)。
- 57.0%患者经历剂量减少,15.6%患者采用替代给药方案,中位平均日剂量为40.0 mg。
- 54.4%患者接受了后续治疗。
- 与更长总生存相关的预测因素包括:体重指数≥25 kg/m2(p=0.0021)、既往肾切除术(p=0.0109)、IMDC风险有利或中等(p<0.0001)以及以60 mg/日起始卡博替尼治疗(p=0.0486)。
临床怎么用
- 在经多线治疗的转移性肾细胞癌患者中,卡博替尼起始剂量60 mg/日与更长总生存相关,但多数患者需剂量调整。
局限性
- 本研究为回顾性观察性研究,可能存在选择偏倚和信息偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Real-world data on cabozantinib in metastatic renal cell carcinoma (mRCC) is limited. This study (CABOREAL) reports treatment patterns and outcomes for patients treated with cabozantinib through the French Early Access Program. PATIENTS AND METHODS: This multicentre (n = 26), observational, retrospective study enrolled patients with mRCC who had received ≥1 dose of cabozantinib. Overall survival (OS) was estimated using the Kaplan-Meier method; subgroups were compared using the log-rank test. A multiple Cox regression model assessed predictive factors of OS after cabozantinib initiation. RESULTS: Four hundred and ten recruited patients started treatment between September 2016 and February 2018: the Eastern Cooperative Oncology Group Performance Status ≥2, 39.3%; poor International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk, 31.7%; 0-1, 2 and ≥3 previous treatment lines, 25.3%, 33.4% and 41.2%, respectively; bone metastases, 55.9%; brain metastases, 16.8%. Median (min-max) follow-up was 14.4 (0-30) months. Overall, 57.0% of patients had a dose reduction, 15.6% an alternative dose schedule. The median average daily dose was 40.0 mg. Median (quartile [Q]1-Q3) treatment duration was 7.6 (0.1-29.1) months, median OS was 14.4 months, and the 12-month OS rate was 56.5% (95% confidence interval: 51.5-61.2). Most patients (54.4%) received subsequent treatment. Predictive factors associated with longer OS were body mass index ≥25 kg/m2 (p = 0.0021), prior nephrectomy (p = 0.0109), favourable or intermediate IMDC risk (p < 0.0001) and cabozantinib initiation at 60 mg/day (p = 0.0486). CONCLUSIONS: In the largest real-world study to date, cabozantinib was effective in unselected, heavily pretreated patients with mRCC. Initiation at 60 mg/day was associated with improved outcomes. CLINICALTRIALS. GOV IDENTIFIER: NCT03744585.
引用
- Albiges L, Fléchon A, Chevreau C, et al. Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program. Eur J Cancer. 2020. PMID: 33253997. doi:10.1016/j.ejca.2020.09.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。